HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials

Springer Science and Business Media LLC - Tập 9 - Trang 1-1 - 2012
JE Volk1, NA Hessol2, GE Gray3, JG Kublin4, G Churchyard5, K Mlisana6, M Nchabeleng7, SP Buchbinder8, L Bekker9
1University of California San Francisco, San Francisco, USA
2Departments of Clinical Pharmacy and of Medicine, UCSF, San Francisco, USA
3Perinatal HIV Research Unit, University of Witwatersrand, Johannesburg, South Africa
4HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, Seattle, USA
5Aurum Institute for Health Research, Klerksdorp, South Africa
6Department of Medical Microbiology, University of KwaZulu-Natal, Congella, South Africa
7Medunsa HIV Clinical Research Unit, University of Limpopo, Limpopo, South Africa
8Department of Public Health, HIV Research Section, San Francisco, USA
9The Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 9

1-1

Thông tin tác giả